International Edition
Latest News
Health

Indira IVF Announces Global Collaboration on Sperm DNA Breaks Research

Nearly 40 percent of global infertility cases stem from male factors. On the occasion of International Men's Day, Indira IVF Hospital Limited announced an international research collaboration targeting male infertility and sperm genomic integrity. The prospective clinical studies…

Indira IVF Announces Global Collaboration on Sperm DNA Breaks Research

Nearly 40 percent of global infertility cases stem from male factors. On the occasion of International Men’s Day, Indira IVF Hospital Limited announced an international research collaboration targeting male infertility and sperm genomic integrity.

The prospective clinical studies will examine the role of double-strand DNA breaks in sperm. Researchers aim to determine how these breaks impact reproductive outcomes, including live birth rates following assisted reproductive technology.

Regional prevalence figures highlight the urgency of the new research initiative. According to Global Burden of Disease data, male infertility prevalence in South Asia increased by nearly 47 percent between 1990 and 2021.

India recorded the highest regional increase, with prevalence rising by almost 59 percent, particularly among young men in their late 20s. Despite insights from conventional sperm DNA fragmentation testing, the clinical significance of double-strand DNA breaks remains insufficiently understood.

The initiative brings together four organisations across three continents following discussions at the American Society for Reproductive Medicine Annual Meeting 2025 in San Antonio, Texas. Indira IVF teamed up with Androfert in Brazil, Bonraybio Co. Ltd. in Taiwan, and ADVY Bioscience Private Limited in India.

Prof. Sandro C. Esteves, medical director of Androfert, will co-lead the initiative alongside Dr. Vipin Chandra from Indira IVF. Participating organisations will contribute complementary expertise spanning clinical research, reproductive medicine, and specialized diagnostic technologies.

Bonraybio will support the programme through specialised diagnostic technologies designed to assess sperm genomic integrity. The company’s contributions aim to provide accurate data for evaluating reproductive outcomes.

“Advancements in reproductive medicine require accurate and reliable diagnostic technologies,” said Brown Hsu, CEO of Bonraybio.

ADVY Bioscience will assist in connecting translational research with clinical applications in male reproductive health. Chetan Raj Singh, president of ADVY Bioscience, said that validating these diagnostic approaches aims to support more informed and effective treatment pathways.

Indira IVF will lead the clinical research activities for the multi-nation programme. The hospital network will provide study materials, analytical frameworks, and methodologies required to evaluate double-strand DNA breaks.

The research seeks to identify the exact threshold at which sperm DNA double-strand breaks begin to affect clinical outcomes. Defining this threshold is expected to support more precise diagnostic approaches and targeted treatment strategies in assisted reproductive technology.

Founded in 1996, Androfert is a Brazilian center dedicated entirely to male infertility and reproductive medicine. Under the leadership of medical director Prof. Sandro C. Esteves, the clinic has built a reputation for scientific development in andrology, conducting research partnerships, presenting at international congresses, and authoring books and chapters on male reproduction.

The initiative continues clinical investigations following its formal launch in November. 20, 2026.

About the author: Health Desk

Health Desk at Archynewsy.